Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

DISEASE CHARACTERISTICS:

* Histologically confirmed metastatic or surgically unresectable solid tumor meeting 1 of the following criteria:

  * Any solid tumor (Phase I)
  * Adenocarcinoma of the stomach or gastroesophageal junction (Phase II)
* Unidimensionally measurable disease by CT scan or MRI
* No uncontrolled brain metastasis

PATIENT CHARACTERISTICS:

* ECOG performance status 0-1
* ANC ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Hemoglobin ≥ 8.0 g/dL
* Creatinine ≤ 1.5 times upper limit of normal (ULN)
* Total bilirubin normal
* Meets 1 of the following criteria:

  * Alkaline phosphatase (AP) normal AND AST or ALT ≤ 5 times ULN
  * AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
  * AP ≤ 5 times ULN AND AST or ALT normal
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for ≥ 3 months after completion of study therapy
* No preexisting neuropathy
* No concurrent uncontrolled illness or other condition that would preclude study compliance
* No history of severe hypersensitivity reaction to docetaxel or to other drugs formulated with polysorbate 80
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in this study

PRIOR CONCURRENT THERAPY:

* Recovered from prior therapy
* More than 4 weeks since prior therapy (Phase I)
* No prior oxaliplatin or taxanes (Phase I)
* More than 4 weeks since prior radiotherapy (Phase I)
* No more than two prior therapies for metastatic disease (Phase I)
* No prior therapy for metastatic disease (Phase II)
* At least 6 months since prior adjuvant therapy (given prior to the occurrence of metastatic disease) (Phase II)
* Prior fluorouracil and concurrent radiotherapy for palliation of the primary tumor allowed provided metastatic disease is present outside the radiotherapy field (Phase II)
* No prior radiotherapy to ≥ 30% of bone marrow
* No other concurrent investigational agents